BENRALIZUMAB (Fasenra) prior authorization at Blue Cross NC
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross NC requires Interleukin-5 Receptor alpha-directed Cytolytic Antibody prior-authorization documentation for BENRALIZUMAB (Fasenra): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Blue Cross NC reviews BENRALIZUMAB (Fasenra) prior authorizations against its medical policy for Interleukin-5 Receptor alpha-directed Cytolytic Antibody. Blue Cross NC-specific context: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-5 Receptor alpha-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross NC's medical policy URL referenced in the cover letter
Blue Cross NC's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Step therapy via Prime Therapeutics
- Blue Premier value-based arrangement disputes
- Out-of-network reductions
- Specialty drug PA
BENRALIZUMAB (Fasenra)-specific denial patterns and context
Across payers (not just Blue Cross NC), BENRALIZUMAB (Fasenra)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Eosinophil count threshold (≥300 cells/µL within 12 months)
- Step therapy requiring mepolizumab first within IL-5 class
- Indication restriction (severe asthma vs EGPA — December 2024)
Brand: Fasenra. IL-5 receptor α monoclonal antibody. Approved for severe eosinophilic asthma; expanded to eosinophilic granulomatosis with polyangiitis (EGPA) September 2024.
Manufacturer patient-assistance program: Benra360 Patient Support — relevant when a Blue Cross NC denial sticks and the patient needs bridge access while appealing.
How Blue Cross NC approaches Biologic drugs (mAbs and biosimilars) PAs
Blue Cross NC's Biologic drugs (mAbs and biosimilars) reviewer typically anchors BENRALIZUMAB (FASENRA) prior-auth decisions on step therapy via prime therapeutics and specialty drug pa. Pharmacy-benefit review for BENRALIZUMAB (FASENRA) at Blue Cross NC is routed through Prime Therapeutics. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Blue Cross NC's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Blue Cross NC is domiciled in NC, so unresolved appeals escalate to the NC insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee for North Carolina (~4.
If the PA is denied
Blue Cross NC gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.bluecrossnc.com/providers) with the same packet plus a peer-reviewed citation supporting BENRALIZUMAB (Fasenra)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross NC denial on DenialHelp.
Contact Blue Cross NC
- Provider portal: https://www.bluecrossnc.com/providers
Frequently asked questions
What documentation does Blue Cross NC need for BENRALIZUMAB (Fasenra) prior auth?
Blue Cross NC's typical PA packet for BENRALIZUMAB (Fasenra): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-5 Receptor alpha-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Blue Cross NC?
Standard BENRALIZUMAB (Fasenra) PA decisions at Blue Cross NC: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Blue Cross NC most often reject BENRALIZUMAB (Fasenra) for?
Across Blue Cross NC's book the common rejection patterns include: Step therapy via Prime Therapeutics; Blue Premier value-based arrangement disputes; Out-of-network reductions. For BENRALIZUMAB (Fasenra) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Blue Cross NC typically require before approving BENRALIZUMAB (FASENRA)?
Blue Cross NC's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For BENRALIZUMAB (FASENRA), attach the specific disease-activity instrument Blue Cross NC accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Blue Cross NC fully-insured policies sits with the NC insurance department.
How do I prep for a peer-to-peer with Blue Cross NC on BENRALIZUMAB (Fasenra)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the BENRALIZUMAB (Fasenra) PA packet
Open ApprovalHelp — generate a BENRALIZUMAB (Fasenra) prior-auth packet tailored to Blue Cross NC's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com